Study: GLP-1 Weight Loss Drugs Linked to Decline in Daily Physical Activity
By
Neuroscience News
Summary
A new study analyzing NIH All of Us Research Program data, including Fitbit activity records and electronic health records, reveals that adults using GLP-1 receptor agonists for weight management experience a significant decline in daily physical activity. Contrary to expectations that weight loss would naturally lead to increased movement, patients showed a sharp drop in daily steps and muscle-preserving physical activity while on these medications.
Source
bskyStudy: GLP-1 Weight Loss Drugs Linked to Decline in Daily Physical Activityneurosciencenews.comKey quotes
· 3 pulledResearchers unmasked a critical behavioral paradox in modern weight management, proving that adults utilizing glucagon-like peptide-1 (GLP-1) receptor agonists experience a significant, measurable decline in daily physical activity.
The findings revealed that instead of naturally moving more as they shed weight, patients experienced a sharp drop in both daily steps and muscle-preserving physical activity.
A new study using NIH Fitbit data reveals that GLP-1 weight loss drugs trigger a significant drop in muscle-preserving physical activity.
You might also wanna read
Study: Stopping GLP-1 Drugs Increases Heart Attack and Stroke Risk
New research published in BMJ Medicine reveals that stopping GLP-1 drugs (originally for diabetes, now popular for weight loss) leads to a r
nautil.us·3mo ago
Study: Most Patients Regain Weight and Lose Health Benefits After Stopping GLP-1 Drugs
A study on tirzepatide (a GLP-1 drug) found that after stopping the medication, 82% of participants regained at least 25% of the weight they
arstechnica.com·6mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·2d ago
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl
medlink.com·6mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
What Happens When You Stop Taking GLP-1 Weight Loss Medications
This article examines the experiences of people who stop taking GLP-1 weight loss medications (like Ozempic and Wegovy), exploring what happ
bbc.com·6mo ago